AdoRx Therapeutics is a UK-based drug discovery company established in 2017, focusing on the development of new cancer therapeutics
AdoRx Therapeutics is a UK-based drug discovery company established in 2017, focusing on the development of new cancer therapeutics. The company’s core strategy is to modulate the adenosine pathway to counteract cancer's ability to evade the immune system. High concentrations of adenosine in the tumor microenvironment suppress immune responses; AdoRx aims to overcome this by designing and developing fit-for-purpose adenosine receptor antagonists.